Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients

Trial Profile

Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2017

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SUCCESS
  • Sponsors Bayer
  • Most Recent Events

    • 04 May 2017 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 May 2017.
    • 12 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top